Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia—Preliminary results from a randomized controlled trial
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractObjectivesThere is great interest in developing and studying novel therapies for epistaxis in hereditary hemorrhagic telangiectasia (HHT) given its associated morbidity and impact on patients' quality of life. Several recent randomized controlled trials (RCTs) have been negative, likely attributed to poorly characterized outcome measures. This study reported on and evaluated an epistaxis outcome measure, weekly epistaxis duration (WED) in an ongoing RCT, with the aim of better characterizing the measurement of epistaxis for clinical trials.Materials and methodsPatients were recruited to an ongoing phase II, double‐blind, cross‐over RCTs of oral doxycycline for HHT‐associated epistaxis. Patients were included for the epistaxis measures analysis if they had already completed the initial 3‐month run‐in period, and had received treatment of either study drug doxycycline or placebo for a minimum of 6 months. The primary measure of interest was patient‐reported outcome (PRO)‐WED, captured from prospective daily diaries. Epistaxis severity score (ESS) was collected as a secondary outcome.ResultsSeven patients were included for analysis, with 98% completion of the daily diary. The average PRO‐WED across all patients was 85.0 minutes, SD 93.2 at baseline, and 65.6 minutes, SD 59.5 during treatment/placebo. Coefficient of variance for PRO‐WED at baseline and during treatment/placebo was 0.49, SD 0.1 and 0.58, SD 0.2, respectively. Statistically significant changes in the mean PRO‐WED from baseline to treatment/placebo was noted in six patients (86%). Only two patients (29%) had a significant change in ESS, with both reporting decreased (improved) scores after treatment/placebo as compared to baseline.ConclusionsPRO‐WED was a feasible clinical trials measure, was reasonably stable during baseline measurement, and appeared to be variable with treatment state, suggesting it may provide a sensitive clinical trials PRO in HHT.
